676560-01-3

Usage

Uses

Used in Pharmaceutical Industry:
3-Pyridinecarboxylic acid, 6-fluoro-, 1,1-dimethylethyl ester is used as a key building block for the production of various drugs and pharmaceutical intermediates. Its unique structure and fluoro substitution on the pyridine ring allow for the development of compounds with modified biological activities, making it a valuable asset in the creation of novel therapeutic agents.
Used in Organic Synthesis:
In the field of organic synthesis, 3-Pyridinecarboxylic acid, 6-fluoro-, 1,1-dimethylethyl ester serves as an important intermediate. Its reactivity and structural features make it suitable for use in the synthesis of a wide range of organic compounds, contributing to the advancement of chemical research and the development of new materials.

Upstream product

• 403-45-2 6-fluoronicotinic acid 
• 36805-97-7 N,N-dimethylformamide di-tert-butyl acetal 
• 65321-36-0 t-butyl nicotinate 
• 75-65-0 tert-butyl alcohol 

Downstream Products

• 813433-93-1 6-(4-amino-4-methyl-cyclohexyloxy)-N,N-dimethyl-nicotinamide 

Relevant academic research and scientific papers

Selective C-H fluorination of pyridines and diazines inspired by a classic amination reaction

Fluorinated heterocycles are prevalent in pharmaceuticals, agrochemicals, and materials. However, reactions that incorporate fluorine into heteroarenes are limited in scope and can be hazardous. We present a broadly applicable and safe method for the site-selective fluorination of a single carbon-hydrogen bond in pyridines and diazines using commercially available silver(II) fluoride. The reactions occur at ambient temperature within 1 hour with exclusive selectivity for fluorination adjacent to nitrogen. The mild conditions allow access to fluorinated derivatives of medicinally important compounds, as well as a range of 2-substituted pyridines prepared by subsequent nucleophilic displacement of fluoride. Mechanistic studies demonstrate that the pathway of a classic pyridine amination can be adapted for selective fluorination of a broad range of nitrogen heterocycles.

Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl] amino-4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): A very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes

Dipeptidyl peptidase-IV (DPP-IV) inhibitors are poised to be the next major drug class for the treatment of type 2 diabetes. Structure-activity studies of substitutions at the C5 position of the 2-cyanopyrrolidide warhead led to the discovery of potent inhibitors of DPP-IV that lack activity against DPP8 and DPP9. Further modification led to an extremely potent (KiDPP-IV = 1.0 nM) and selective (KiDPP8 > 30 μM; KiDPP9 > 30 μM) clinical candidate, ABT-279, that is orally available, efficacious, and remarkably safe in preclinical safety studies.

Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)

The present invention relates to compounds that inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclero

Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)

The present invention relates to compounds which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atheroscler

PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV)

The present invention relates to compounds which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases.